Huvitz Co. Ltd (065510) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Huvitz Co. Ltd KRW 6,232, price KRW 6,610, upside -5.7%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Huvitz Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 6,410 KRW – 23,601 KRW · fair‑value band 6,232 KRW – 6,910 KRW · the 6,610 KRW price screens above the 6,232 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Huvitz Co. in your weekly email
Every Wednesday you see whether Huvitz Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Huvitz Co., Ltd. develops and sells optometric medical equipment worldwide.
Show more
Huvitz Co., Ltd. develops and sells optometric medical equipment worldwide. The company offers ophthalmic and optical equipment comprising refractive equipment, such as auto ref-keratometers, auto lensmeters, digital refractors, chart projectors, and unit tables; and diagnostic equipment comprising slit lamps, non-contact tonometers, and applanation tonometers, as well as ophthalmologic diagnostic and surgical systems. It also provides edging solutions, such as edgers, frame readers, auto-blockers with frame readers, blockers, drilling machines, and network solutions; and visual acuity testers and microscope systems. The company was formerly known as Mirae Optics Co., Ltd. and changed its name to Huvitz Co., Ltd. in 2002. Huvitz Co., Ltd. was founded in 1998 and is based in Anyang-si, South Korea.
Stock analysis
Huvitz Co. Ltd (065510) currently trades at 6,610 KRW, while our model-based Fair Value estimate is 6,232 KRW, implying the stock looks roughly 6.1% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 12,123 KRW per share, and 11 of the 13 models we run sit above the 6,610 KRW price.
Bear case: the Earnings-Based group reads lowest at 5,879 KRW, and 2 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: 6,232 KRW (bear) to 6,910 KRW (bull), the price of 6,610 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Huvitz Co. Ltd reported revenue of 118B KRW in FY2025 versus 95.0B KRW in FY2021, a compound +5.6%/yr. Reported net income was −5.0B KRW in FY2025.
Key figures
Market cap 70.0B KRW (≈ $49.0M) · P/S ratio 0.60 · Dividend yield 3.8% · Net margin −4.2% · Return on equity −3.2% · Return on assets (EBIT) 5.1% · Operating margin 8.8% · Revenue (TTM) 118B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 32% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −6%, 065510 screens richer than that median.
Fair Value models
Bear 6,232 KRWFair Value 6,232 KRWBull 6,910 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2020 (pandemic). Over 10 years: +5.4% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.3% (2020) → 4.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +10.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score43 · Below median
Fair Value upside−6% · Above median
Profitability
Return on assets1% · Above median
Net margin (TTM)−3% · Below median
Operating margin (TTM)9% · Above median
Growth and dividend
Revenue growth−1% · Below median
Dividend yield (TTM)3.8% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Huvitz Co. Ltd (065510) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 6,232 KRW versus a price of 6,610 KRW, about −6% upside (fairly valued).
What is the fair value of 065510?
Our model-based fair value for Huvitz Co. Ltd is 6,232 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 6,610 KRW.
What is the quality score of 065510?
Huvitz Co. Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Huvitz Co. Ltd (065510)?
Our model-based price target is the fair value of 6,232 KRW (as of Sep 24, 2026) from 13 valuation models. Cautious scenario 6,232 KRW, optimistic scenario 6,910 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Huvitz Co. Ltd stock forecast for 2026?
Our models put fair value at 6,232 KRW, about −6% upside versus a price of 6,610 KRW (fairly valued). Cautious scenario 6,232 KRW, optimistic scenario 6,910 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Huvitz Co. Ltd (065510)?
Huvitz Co. Ltd reported trailing-twelve-month revenue of about 118B KRW (latest available figure, as of Sep 24, 2026).
Does Huvitz Co. Ltd pay a dividend?
Huvitz Co. Ltd currently shows a dividend yield of about 3.78% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Huvitz Co. Ltd (065510)?
For today's price to be fair in a discounted-cash-flow model, Huvitz Co. Ltd would have to grow free cash flow by +13.0 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 065510 use?
Our models discount Huvitz Co. Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.25, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Huvitz Co. Ltd that is +13.0 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Huvitz Co. Ltd (065510) delivered so far?
Over the past 5 years revenue at Huvitz Co. Ltd grew +11.0 % a year. The price currently implies +13.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Huvitz Co. Ltd (065510) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Huvitz Co. Ltd (+13.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Huvitz Co. Ltd (065510)?
The free-cash-flow yield on the price is 7.21 %: that much free cash flow Huvitz Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Huvitz Co. Ltd (065510)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Huvitz Co. Ltd it is 6,232 KRW per share (as of Sep 24, 2026), against a price of 6,610 KRW. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Huvitz Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 065510 trades above its calculated fair value: price 6,610 KRW, fair value 6,232 KRW, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 065510?
No. The price is what the market pays today (6,610 KRW); the fair value is what the company's own numbers justify (6,232 KRW). For Huvitz Co. Ltd the two are 378.29 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Huvitz Co. Ltd worth?
The market values Huvitz Co. Ltd at about 70.0B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 6,610 KRW; our models calculate a fair value of 6,232 KRW per share.
What do the bullish and bearish scenarios say about 065510?
Our models span a range for Huvitz Co. Ltd: cautious scenario 6,232 KRW, base 6,232 KRW, optimistic 6,910 KRW per share (as of Sep 24, 2026, price 6,610 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Huvitz Co. Ltd (065510)?
Balance-sheet figures for Huvitz Co. Ltd (as of Sep 24, 2026): return on equity −3.2%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 065510 from its 52-week high?
Huvitz Co. Ltd trades at 6,610 KRW, about 32% below its 52-week high of 9,720 KRW and 3% above the low of 6,410 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 6,232 KRW is for.
Which stocks are comparable to Huvitz Co. Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Huvitz Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 6,610 KRW, calculated fair value 6,232 KRW (−6%), Quality Score 43/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 065510 calculated?
We run Huvitz Co. Ltd through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6,232 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Huvitz Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Huvitz Co. Ltd (065510)?
The closing price on Sep 23, 2026 was 6,610 KRW. Our model-based fair value is 6,232 KRW, about −6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Huvitz Co. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (6,232 KRW to 6,910 KRW), unusually little disagreement for a valuation.
Key figures of Huvitz Co. Ltd
How large is the market capitalisation of Huvitz Co. Ltd (065510)?
The market capitalisation of Huvitz Co. Ltd is 70.0B KRW (≈ $49.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Huvitz Co. Ltd (065510)?
The price-to-sales ratio of Huvitz Co. Ltd is 0.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Huvitz Co. Ltd (065510)?
The dividend yield of Huvitz Co. Ltd is 3.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Huvitz Co. Ltd (065510)?
The net margin of Huvitz Co. Ltd is −4.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Huvitz Co. Ltd (065510)?
The return on equity (ROE) of Huvitz Co. Ltd is −3.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Huvitz Co. Ltd (065510)?
On an EBIT basis the return on assets of Huvitz Co. Ltd is 5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Huvitz Co. Ltd (065510)?
The operating margin of Huvitz Co. Ltd is 8.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Huvitz Co. Ltd (065510)?
Revenue at Huvitz Co. Ltd is growing −0.7% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Huvitz Co. Ltd (065510)?
Earnings per share at Huvitz Co. Ltd are growing +49.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Huvitz Co. Ltd (065510) carry?
The net debt of Huvitz Co. Ltd is 66.8B KRW (fiscal year 2025, ≈ 13.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Huvitz Co. Ltd in the live analysis
One click puts Huvitz Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
